Congenital Heart Defect Devices Market Size, Share & Industry Analysis, By Product Type (Defect Closure Devices, Congenital Heart Stents, Transcatheter Pulmonary Valves, Balloon Dilatation Catheters, and Others), By Application (Septal Defects, Patent Ductus Arteriosus, RVOT & Pulmonary Valve Dysfunction, Great Vessel Obstruction, and Others), By Technology (Occlusion Technology, Balloon-Expandable Technology, Self-Expanding Technology, Balloon Dilatation Technology, and Others), By End User (Hospitals, Cardiac Specialty Centers, and Others), and Regional Forecast, 2026–2034

The global congenital heart defect devices market size was valued at USD 921.5 million in 2025. The market is projected to grow from USD 998.9 million in 2026 to USD 1,964.9 million by 2034, exhibiting a CAGR of 8.8% during the forecast period.

Congenital heart defect devices are implantable or catheter-based medical devices used to treat structural heart abnormalities present from birth. These technologies include septal defect closure devices, patent ductus arteriosus occluders, congenital heart stents, transcatheter pulmonary valves, and balloon dilatation catheters. The market growth is primarily driven by the high burden of congenital heart defects, increasing diagnosis through prenatal and newborn screening, pediatric cardiology devices, growing adoption of minimally invasive transcatheter procedures, and technological advancements that enable treatment of smaller and more anatomically complex pediatric patients. Moreover, the development of lower-profile delivery systems, self-expanding devices, and transcatheter pulmonary valves is further expanding the addressable patient population.

• For instance, in December 2025, Abbott received CE Mark and FDA clearance for its Amplatzer Piccolo Delivery System, enabling precise catheter-based closure of patent ductus arteriosus in premature infants.

Furthermore, Abbott, Medtronic, Edwards Lifesciences Corporation, LifeTech Scientific Corporation, and W. L. Gore & Associates, Inc. are among the prominent companies operating in the global market.

CONGENITAL HEART DEFECT DEVICES MARKET TRENDS

Increasing Shift toward Minimally Invasive Transcatheter Correction of Congenital Heart Defects

The market is witnessing a strong shift toward minimally invasive transcatheter interventions that reduce reliance on open-heart surgery for selected congenital abnormalities. Transcatheter defect closure has become an important treatment approach for atrial septal defects and patent ductus arteriosus, while advancements in self-expanding frames, low-profile delivery systems, and imaging guidance are expanding treatment possibilities across a wider range of anatomically complex cases. In addition, transcatheter pulmonary valves are enabling patients with right ventricular outflow tract dysfunction to receive pulmonary valve replacement without the need for repeat open-heart procedures. Manufacturers are focusing on smaller delivery profiles, flexible and conformable implant designs, repositionability, improved sealing, and technologies suitable for pediatric and adult congenital populations. The development of devices specifically intended for smaller patients and anatomically diverse RVOT configurations is expected to further accelerate the transition toward catheter-based congenital heart interventions.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Survival Rates and Growing Need for Long-Term Cardiac Management to Drive Market Growth

Improving survival rates among infants and children diagnosed with congenital heart defects are increasing the population of adolescents and adults requiring lifelong cardiac management and propelling product demand, driving congenital heart defect devices market growth. Advances in neonatal intensive care, pediatric cardiac surgery, and postoperative management have enabled more patients with complex congenital abnormalities to survive into adulthood. In addition, patients with previously repaired defects may develop residual shunts, valve deterioration, arrhythmias, or other late complications requiring additional cardiac interventions. Moreover, increasing demand for specialized adult congenital heart disease services and regular cardiac follow-up is supporting the utilization of implantable cardiovascular medical devices and corrective technologies. This growing population requiring ongoing treatment is expected to sustain market demand.

MARKET RESTRAINTS

High Procedure Costs and Limited Access to Specialized Pediatric Cardiac Care May Restrict Market Growth

The high costs associated with congenital cardiac interventions and limited access to specialized pediatric cardiology infrastructure remain major restraints to market expansion. Transcatheter treatment requires advanced catheterization laboratories, imaging capabilities, pediatric interventional cardiologists, anesthesia support, specialized device inventories, and experienced multidisciplinary teams. These resources are disproportionately concentrated within major tertiary and academic hospitals, particularly in lower-income healthcare systems. These limitations associated with infrastructure, affordability, and specialist access may constrain adoption despite increasing availability of minimally invasive congenital heart technologies.

MARKET OPPORTUNITIES

Expansion of Congenital Heart Disease Screening and Early Diagnosis Programs to Create Growth Opportunities

Increasing investments in congenital heart disease screening and early diagnosis programs are creating significant growth opportunities for market players. Expansion of prenatal cardiac screening, newborn pulse oximetry testing, and pediatric echocardiography services is improving the identification of structural heart abnormalities during early stages of life. In addition, government initiatives aimed at strengthening maternal and child healthcare infrastructure are supporting the establishment of pediatric cardiology departments and specialized cardiac referral networks, particularly in emerging economies. Moreover, increasing availability of diagnostic services in underserved regions is expected to improve patient referrals for corrective interventions, thereby expanding the addressable patient population and creating opportunities for congenital heart defect device manufacturers.

MARKET CHALLENGES

Complex and Highly Variable Congenital Cardiac Anatomy to Create Challenges in Device Development

Congenital heart defects encompass a broad range of structural abnormalities with substantial variation in lesion size, vascular anatomy, patient age, body weight, previous surgical repairs, and long-term hemodynamic requirements. This variability complicates the development of standardized device solutions and may require manufacturers to offer multiple sizes and delivery configurations. Devices intended for infants and children must accommodate small access vessels while maintaining sufficient radial strength, sealing, flexibility, and long-term durability. Further, the growth of pediatric patients also creates unique challenges because implanted devices remain in place as anatomy changes over time. Complex congenital anatomies may remain unsuitable for device-based treatment and require surgical repair. Furthermore, the small size and physiological differences of infants and young children can increase procedural complexity and restrict device selection. Moreover, transcatheter interventions require accurate imaging and procedural planning to minimize risks such as device embolization, residual shunting, vascular injury, obstruction, arrhythmias, and interference with surrounding structures.

Segmentation Analysis

By Product Type

Defect Closure Devices Segment Led the Market due to High Utilization in Septal and Ductus Closure Procedures

Based on product type, the market is segmented into defect closure devices, congenital heart stents, transcatheter pulmonary valves, balloon dilatation catheters, and others.

The defect closure devices segment held the largest share of the global market in 2025. These devices are widely used for transcatheter treatment of atrial septal defects, patent ductus arteriosus, and other selected congenital shunts. Moreover, increasing adoption of minimally invasive defect closure, availability of self-expanding occluders, broader physician experience, and continued development of devices suitable for smaller pediatric patients are supporting segment dominance.      

The transcatheter pulmonary valves segment is anticipated to grow at the highest CAGR of 10.9% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Application

Septal Defects Segment Accounted for Major Share owing to High Prevalence and Established Transcatheter Closure Approaches

Based on application, the market is segmented into septal defects, patent ductus arteriosus, RVOT & pulmonary valve dysfunction, great vessel obstruction, and others.

The septal defects segment held the highest share of the global market in 2025. Atrial and ventricular septal defects represent important congenital structural heart abnormalities, and selected defects can be treated through transcatheter closure using occluder devices. Growing diagnosis, improvements in interventional imaging, and availability of dedicated closure systems continue to support segment demand.

The RVOT & pulmonary valve dysfunction segment is projected to register the highest CAGR of 10.7% during the forecast period.

By Technology

Established Use of Transcatheter Closure Devices Supported Occlusion Technology Segment Dominance

Based on technology, the market is segmented into occlusion technology, balloon-expandable technology, self-expanding technology, balloon dilatation technology, and others.

The occlusion technology segment accounted for the highest congenital heart defect devices market share in 2025. Occlusion technologies are widely utilized for closure of atrial septal defects, patent ductus arteriosus, and other structural shunts. In addition, established clinical adoption of nitinol-based occluders, availability of multiple device sizes, and continued improvements in delivery systems are supporting segment dominance.

The self-expanding technology segment is projected to record the highest CAGR of 11.3% during the forecast period.

By End User

Hospitals Segment Dominated the Market due to Concentration of Pediatric Interventional Cardiology Infrastructure

Based on end user, the market is segmented into hospitals, cardiac specialty centers, and others.

The hospitals segment held the largest share of the global market in 2025. Congenital cardiac interventions are primarily performed in tertiary hospitals equipped with pediatric cardiology, cardiac surgery, catheterization laboratories, advanced imaging, anesthesia, intensive care, and multidisciplinary clinical support. These infrastructure requirements strongly concentrate device utilization within hospital settings.

The cardiac specialty centers segment is expected to register the highest CAGR of 11.1% during the forecast period.

Congenital Heart Defect Devices Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, with a value of USD 333.6 million, and maintained the leading share in 2025, with USD 362.1 million. Strong pediatric cardiac infrastructure, widespread prenatal and newborn screening, availability of interventional congenital heart centers, high adoption of defect closure devices, and early access to innovative transcatheter pulmonary valve technologies are supporting market leadership.

U.S. Congenital Heart Defect Devices Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market is estimated to reach around USD 357.7 million in 2026, accounting for roughly 35.8% of global sales.

Europe

Europe is projected to reach a valuation of USD 268.8 million by 2026 and record a considerable CAGR of 7.2% over the forecast period. The region benefits from established pediatric cardiac centers, organized congenital heart disease treatment pathways, increasing utilization of minimally invasive interventions, and availability of advanced transcatheter technologies.

U.K. Congenital Heart Defect Devices Market

The U.K. market is estimated to reach around USD 46.5 million in 2026, representing roughly 4.7% of global revenues.

Germany Congenital Heart Defect Devices Market

The Germany market is projected to reach approximately USD 58.5 million in 2026, equivalent to around 5.9% of global sales.

Asia Pacific

Asia Pacific is estimated to hold a considerable share in the global market in 2026 with a value of USD 252.9 million. Growth is supported by large pediatric populations, improving congenital heart disease diagnosis, expansion of pediatric cardiology and cardiac surgery infrastructure, increasing healthcare expenditure, and greater availability of transcatheter devices across China, Japan, India, and other Asia Pacific markets.

Japan Congenital Heart Defect Devices Market

The Japan market is estimated to reach around USD 50.7 million in 2026, accounting for roughly 5.1% of global revenues.

China Congenital Heart Defect Devices Market

The China market is projected to be one of the largest worldwide, with 2026 revenues estimated at around USD 76.7 million, representing roughly 7.7% of global sales.

India Congenital Heart Defect Devices Market

The India market is estimated to reach around USD 36.8 million in 2026, accounting for roughly 3.7% of global revenues.

Latin America and the Middle East & Africa

Latin America and the Middle East & Africa regions are expected to witness moderate growth during the forecast period. The Latin America market is set to reach a valuation of USD 52.3 million in 2026. In the Middle East & Africa, the GCC is set to reach a value of USD 16.4 million in 2026.

South Africa Congenital Heart Defect Devices Market

The South Africa market is projected to reach around USD 8.0 million in 2026, representing roughly 0.8% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Leading Players Offer Next-Generation Robotic Platforms and Integrated Digital Surgery Ecosystems to Secure a Competitive Advantage

The global congenital heart defect devices market has a semi-consolidated competitive structure, comprising prominent players such as Abbott, Medtronic, Edwards Lifesciences Corporation, LifeTech Scientific Corporation, and W. L. Gore & Associates, Inc. These market players are focusing on defect-specific device portfolios, delivery-system profiles, implant flexibility, repositionability, size range, long-term clinical evidence, regulatory approvals, geographic reach, and physician training with an aim to maintain their market share.

• For instance, in March 2026, Starlight Cardiovascular announced the first implantation of its Lifeline Ductus Arteriosus Stent System in an infant with congenital heart disease, advancing minimally invasive neonatal cardiac interventions.

Other notable players in the global market are expected to prioritize collaborations to increase their global market share during the forecast period.

LIST OF KEY CONGENITAL HEART DEFECT DEVICES COMPANIES PROFILED

• Abbott (U.S.)
• Medtronic (Ireland)
• Edwards Lifesciences Corporation (U.S.)
• LifeTech Scientific Corporation (China)
• L. Gore & Associates, Inc. (U.S.)
• Occlutech Holding AG (Switzerland)
• LEPU Medical Technology (Beijing) Co., Ltd. (China)
• NuMED, Inc. (U.S.)
• Venus Medtech (Hangzhou) Inc. (China)
• Meril Life Sciences Pvt. Ltd. (India)

KEY INDUSTRY DEVELOPMENTS

• October 2026: Edwards Lifesciences received U.S. FDA approval for its AUTUS Size-Adjustable Valve, designed for pediatric congenital heart disease patients, enabling valve expansion as children grow and potentially reducing repeat surgeries.
• June 2026: Shanghai Jinkui Medical received Chinese regulatory approval for its self-expanding, biodegradable atrial septal defect occluder, advancing minimally invasive congenital heart defect closure with an innovative bioabsorbable device design.
• January 2025: Medtronic received CE Mark for the Harmony Transcatheter Pulmonary Valve System for patients with congenital heart disease and native or surgically repaired right ventricular outflow tracts, expanding access to minimally invasive pulmonary valve replacement in Europe.
• September 2024: L. Gore & Associates released three-year clinical data for the GORE CARDIOFORM ASD Occluder, reporting sustained defect-closure outcomes from the ASSURED Clinical Study.
• August 2024: Occlutech announced the first commercial implantation cases of the Occlutech ASD Occluder in the U.S., representing an important milestone in the company's U.S. commercialization following regulatory approval.

REPORT COVERAGE

The global congenital heart defect devices market analysis includes a comprehensive study of the market size and forecast across all the segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It provides information on key aspects, including an overview of technological advancements, the regulatory environment, and product launches. Additionally, it details partnerships, mergers, acquisitions, key industry developments, and investments by key regions. The global market research report also provides an in-depth competitive landscape with information on the market share and profiles of key operating players.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1: Country-Level Congenital Heart Procedure & Device Utilization Analysis

• Estimate country-level patients requiring device-based intervention for congenital structural heart abnormalities, including septal defects, patent ductus arteriosus, RVOT and pulmonary valve dysfunction, and great-vessel obstruction.
• Assess diagnosed congenital heart defect populations, pediatric and adult congenital patient pools, catheter-based intervention volumes, congenital cardiac surgery volumes, and availability of specialist cardiac centers.
• Estimate market value based on Eligible Patient Population × Device-Based Treatment Penetration × Device Utilization per Procedure × Average Selling Price.
• Adjust estimates for treatment access, reimbursement, procurement discounts, local pricing, import dependence, and regulatory availability.
• Aggregate country-level estimates into regional and global market totals.

Approach 2: Procedure Volume, Device Penetration & ASP Analysis

• Estimate annual procedure volumes across septal defects, patent ductus arteriosus, RVOT & pulmonary valve dysfunction, great vessel obstruction, and others.
• Estimate device utilization across defect closure devices, congenital heart stents, transcatheter pulmonary valves, balloon dilatation catheters, and others.
• Calculate market value using Procedure Volume × Device Penetration × Devices per Procedure × Manufacturer ASP.
• Cross-check estimates against manufacturer revenues, hospital procurement, regulatory approvals, published procedure volumes, product catalogs, and congenital heart registries.

Approach 3: Secondary & Institutional Data Cross-Check

• Validate market assumptions using FDA databases, European regulatory authorities, congenital heart defect epidemiology databases, national pediatric cardiology organizations, congenital heart registries, ClinicalTrials.gov, PubMed, and peer-reviewed interventional cardiology literature.
• Track approvals, product launches, clinical outcomes, screening rates, congenital cardiac procedure growth, and geographical expansion.
• Exclude third-party market research estimates as primary evidence.

2. Top Down Approaches

Approach 1: Revenue & Market Share Analysis of Major Manufacturers/Developers

• Estimate congenital heart device-attributable revenue for major manufacturers using annual reports, regulatory filings, company disclosures, device portfolios, unit sales, product availability, and geographical presence.
• Allocate attributable revenues across defect closure devices, congenital heart stents, transcatheter pulmonary valves, balloon dilatation catheters, and relevant delivery systems.
• Exclude unrelated adult structural heart, coronary, electrophysiology, general vascular, and cardiac surgery revenues.
• Compare aggregated manufacturer-derived revenues with bottom-up market calculations.

Approach 2: Triangulation, Validation, and Forecast Modeling

• Compare manufacturer revenue, congenital procedure volumes, diagnosed patient populations, device penetration, ASPs, product launches, regulatory approvals, and geographical availability.
• Reconcile differences using conservative, base-case, and higher-growth scenarios.
• Forecast country-level markets first and aggregate them into regional and global totals.
• Calculate CAGR using (1,964.9 / 998.9)^(1/8) − 1 ≈ 8.8%.
• Ensure reconciliation across product type, application, technology, end user, region, and global market totals.

3. List of Key Sources

• Company annual reports
• SEC and regulatory filings
• Investor presentations
• Quarterly earnings disclosures
• Official company websites
• Product catalogs
• Product manuals and instructions for use
• S. FDA PMA database
• S. FDA 510(k) database
• FDA pediatric device approvals
• European Commission / EU MDR
• CE certification documentation
• EUDAMED
• PMDA / MHLW
• NMPA
• CDSCO
• TGA
• CDC congenital heart defect data
• WHO
• National ministries of health
• National congenital heart disease registries
• Pediatric and congenital cardiology societies
• Pediatric and Congenital Interventional Cardiovascular Society
• Society for Cardiovascular Angiography & Interventions
• American Heart Association
• American College of Cardiology
• European Society of Cardiology
• Congenital cardiac surgery registries
• Hospital procurement databases
• Government tender databases
• gov
• PubMed
• Peer-reviewed pediatric cardiology journals
• Peer-reviewed structural heart journals
• Interventional cardiology journals
• Product approval announcements
• Company press releases
• Clinical study publications
• Partnership and distribution announcements

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents: Congenital heart defect device manufacturers, structural heart manufacturers, occluder manufacturers, pediatric catheter manufacturers, congenital stent manufacturers, transcatheter pulmonary valve manufacturers, delivery-system manufacturers, nitinol suppliers, OEMs, product managers, R&D executives, regulatory professionals, regional sales executives, commercial heads, and business development executives.
• Validate congenital heart device-attributable manufacturer revenues.
• Validate annual device shipments and sales volumes.
• Validate ASP ranges.
• Validate product type mix.
• Validate application mix.
• Validate technology mix.
• Validate end user mix.
• Validate country and regional sales distribution.
• Validate hospital and distributor procurement channels.
• Validate regulatory availability.
• Validate device sizing and pediatric applicability.
• Validate delivery system profiles.
• Validate occlusion versus self-expanding technology allocation.
• Validate transcatheter pulmonary valve penetration.
• Validate device replacement and repeat intervention trends.
• Validate pricing and reimbursement trends.
• Validate geographical expansion.
• Validate expected technology migration through 2034.

Demand Side Interviews: 40%

• Key Respondents: Pediatric cardiologists, congenital interventional cardiologists, adult congenital heart specialists, pediatric cardiac surgeons, structural heart specialists, catheterization laboratory directors, cardiac specialty center administrators, pediatric hospital procurement teams, cardiac nurses, biomedical engineers, and hospital purchasing organizations.
• Validate annual congenital cardiac intervention volumes.
• Validate diagnosed versus treated congenital heart defect populations.
• Validate device utilization by procedure.
• Validate septal defect and PDA closure volumes.
• Validate congenital stent utilization.
• Validate transcatheter pulmonary valve volumes.
• Validate balloon dilatation procedure volumes.
• Validate patient age and weight considerations.
• Validate device size preferences.
• Validate procedural success and repeat intervention requirements.
• Validate procurement prices and discounts.
• Validate hospital versus cardiac specialty center utilization.
• Validate treatment barriers, including high costs, limited specialist availability, complex anatomy, and access to catheterization laboratories.
• Validate future demand arising from expanded newborn screening, increasing survival of congenital heart disease patients, growth of transcatheter interventions, pediatric-specific device innovation, and improved access to congenital cardiac care.